Efficacy of steroid treatment and identification of prognostic factors in idiopathic peripheral facial nerve palsy in children
Öz
Purpose: The aim of the study is intended to investigate the etiology and clinical features of children with idiopathic peripheral facial palsy (IPFP) and to identify probable prognostic factors. It is also intended to investigate corticosteroid therapy and compare its efficacy.
Materials and Methods: A total of 80 patients with newly diagnosed IPFP were included in the study. Demographic, clinical features and laboratory findings including age, gender, House Brackmann Facial Nerve Grading System (HBGS) grade at admission and follow-up, and the dosage and onset of steroid treatment were reviewed. We assigned our patients to 3 groups: Group 1: Patients given 1 mg/kg oral steroid treatment (1 mg/kg/day oral prednisolone). Group 2: Patients given 2 mg/kg oral steroid treatment (2 mg/kg/day oral prednisolone), and Group 3: Patients who did not receive oral steroid treatment.
Results: A total of 80 children (41 girls and 39 boys) with a median age of 11 years were included in the study. The complete recovery was detected in %78,8(n:63) with IPFP. Of all patients, 78.8% (n=63) showed complete recovery. Admission after more than 24 hours was found to reduce the likelihood of ER by 10 times (1/0.10), while patients with HBGS grade of 5 were found to be 33.3 times (1/0.03) less likely to achieve ER than patients with HBGS grades of 2 to 3. Finally, steroid treatment at 2 mg/kg/d increased the probability of early recovery by 8.38 times.
Conclusion: The prognosis of IPFP in children was very good. The prognostic factors affecting the early recovery were being HBGS grade 2 or 3 on the 21th day and receiving steroid treatment in the first 24 hours and 2 mg/kg/d dose.
Anahtar Kelimeler
Idiopathic peripheral facial palsy (IPFP), bell’s palsy, children, prognosis
Kaynakça
- 1. Jenke AC, Stoek LM, Zilbauer M, Wirth S, Borusiak P. Facial palsy: etiology, outcome and management in children. Eur J Paediatr Neurol. 2011;15:209-13.
- 2. S. G. Yeo, Y. C. Lee, D. C. Park, and C. I. Cha, “Acyclovir plus steroid vs steroid alone in the treatment of Bell’s palsy,” American Journal of Otolaryngology-Head and Neck Medicine and Surgery. 2008;29(3):163–166.
- 3. Jackson CG, von Doersten PG. The facial nerve: current trends in diagnosis, treatment, and rehabilitation. Med Clin North Am. 1999;83:179-195.
- 4. Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl. 2002:4-30.
- 5. Kanerva M, Nissinen J, Moilanen K, Maki M, Lahdenne P, Pitkaranta A. Microbiologic findings in acute facial palsy in children. Otol. Neurotol. 2013;34:82-7.
- 6. Abramsky O, Webb C, Teitelbaum D, et al. Cellular immune response to peripheral nerve basic protein in idiopathic facial paralysis (Bell’s palsy). J Neurol Sci. 1975;26:13–20.
- 7. McCormick DP. Herpes simplex virus as a cause of Bell’s palsy. Lancet 1972;1:937.
- 8. Leibowitz U. Epidemic incidence of Bell’s palsy. Brain 1969;92:109–114.
- 9. Kynvett AF. Viral infection of the nervous system. Med J Aust 1959;2:118–121.
- 10. De Diego JI, Prim MP, De Sarria MJ, et al. Idiopathic facial paralysis: a randomized, prospective, and controlled study using single döşe prednisone versus acyclovir three times daily. Laryngoscope 1998;108:573–575.
